KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Accumulated Depreciation: 2020-2022

Historic Accumulated Depreciation for AbCellera Biologics (ABCL) over the last 3 years, with Dec 2022 value amounting to $18.5 million.

  • AbCellera Biologics' Accumulated Depreciation rose 88.02% to $18.5 million in Q4 2022 from the same period last year, while for Dec 2022 it was $18.5 million, marking a year-over-year increase of 88.02%. This contributed to the annual value of $18.5 million for FY2022, which is 88.02% up from last year.
  • AbCellera Biologics' Accumulated Depreciation amounted to $18.5 million in FY2022, which was up 88.02% from $9.8 million recorded in FY2021.
  • AbCellera Biologics' 5-year Accumulated Depreciation high stood at $18.5 million for FY2022, and its period low was $5.6 million during FY2020.
  • For the 3-year period, AbCellera Biologics' Accumulated Depreciation averaged around $11.3 million, with its median value being $9.8 million (2021).
  • Data for AbCellera Biologics' Accumulated Depreciation shows a peak YoY surged of 88.02% (in 2022) over the last 5 years.
  • Over the past 3 years, AbCellera Biologics' Accumulated Depreciation (Yearly) stood at $5.6 million in 2020, then skyrocketed by 75.90% to $9.8 million in 2021, then soared by 88.02% to $18.5 million in 2022.